

## Appendix 4E

IDT Australia Limited

ASX Preliminary final report for the year ended 30 June 2017

Lodged with the ASX under Listing Rule 4.3A

### Results for Announcement to the Market

				\$'000
<b>Revenue</b> from ordinary activities (*)	<b>up</b>	25%	to	<b>9,543</b>
<b>Operating Loss before Tax</b> before Tax and Impairment of Intangible Assets	<b>up</b>	25%	to	<b>(7,224)</b>
<b>Profit from Discontinued Operation</b> (CMAX)				<b>13,730</b>
<b>Total Loss</b> from Continuing Operations before Tax	<b>up</b>	255%	to	<b>(14,503)</b>
<b>Loss</b> for the period attributable to members	<b>down</b>	81%	to	<b>(773)</b>

(\*) Excludes CMAX which has been recategorised as a discontinued operation

**Dividend Information** – there are no interim or final dividends declared or recommended for the financial year ended 2017 (nil 2016).

**Net tangible assets per security** as at 30 June 2017 \$0.12 (\$0.10 2016).

**Additional Appendix 4E disclosure requirements** can be found in the Annual Report which contains the Report of the Directors and the 30 June 2017 Financial Statements and accompanying notes.

The report is based on the Financial Statements which have been audited by Deloitte Touche Tohmatsu.

### Highlights

Following the divestment of the initial 61% of CMAX for \$10 million in December 2016 the company is holding cash reserves of \$8.4 million at 30 June 2017. A further \$6.1 million for divestment of the final 39% is due to be received early in financial year 2018 which means the company is well placed to continue to invest in its new product pipeline and in turn support further new product launches next year and beyond.

IDT launched its first proprietary finished dose form product in October 2016, Temozolomide, and this was followed by Pindolol in April 2017, being the first of the acquired ANDAs to be launched. These products realised first year sales revenues of \$1.3 million with initial profit shares received of around \$0.1 million. Our distribution partners are winning new contracts with these products and we are looking to continue to launch new products. We remain confident that contributions from the ANDA's portfolio will continue to grow.